Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 15|pp 19475—19485

FK506 binding protein 10: a key actor of collagen crosslinking in clear cell renal cell carcinoma

Yubai Zhang1,4, Yue Yin2, Sijia Liu3, Lei Yang1,4, Changhua Sun4, Ruihua An1
  • 1Department of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
  • 2Department of Oncology Radiotherapy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
  • 3Department of Gynecological Radiotherapy, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
  • 4Department of Urology Surgery, The First Hospital of Harbin, Harbin, China
Received: May 27, 2021Accepted: July 10, 2021Published: August 13, 2021
https://doi.org/10.18632/aging.203359

Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common type of malignant tumor in the kidney. With numbers of patients whose physical condition or tumor stage not suitable for radical surgery, they only have a narrow choice of using VEGF/mTOR targeted drugs to control their tumors, but ccRCC often shows resistance to these drugs. Therefore, identifying a new therapeutic target is of urgent necessity. In this study, for the first time, we concluded from bioinformatics analyses and in vitro research that FK506 binding protein 10 (FKBP10), together with its molecular partner Lysyl hydroxylase 2 (LH2/PLOD2), participate in the process of type I collagen synthesis in ccRCC via regulating crosslinking of pro-collagen chains. Our findings may provide a potential therapeutic target to treat ccRCC in the future.